Clinic'n'Cell
4
0
1
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 4 trials
100.0%
+13.4% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (4)
A Clinical Trial Evaluating the Influence of the Ingredients MyCondro™ and Bovine Chondroitin Sulfate on the Behavior of Cells in the Osteoarticular Sphere
Role: collaborator
Determination of Biological Activity of Human-enriched Serum Following Chondractiv™ Plus Ingredient Ingestion
Role: collaborator
Determination of the Biological Activity of Enriched Serums on Healthy Volunteers After Consumption of the Kera-Diet® Ingredient
Role: collaborator
Determination of Biological Activity of Enriched Serum Following TOTUM-448 Consumption
Role: collaborator
All 4 trials loaded